AEHR · XBRL financial data

Aehr Test Systems financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal quarters (AEHR's year ends in late May)

In thousands of dollars	Q1 FY24Aug 31, 2023	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25Nov 29, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 30, 2025	Q1 FY26Aug 29, 2025	Q2 FY26Nov 28, 2025	Q3 FY26Feb 27, 2026	Q4 FY26May 29, 2026
Revenue	—	—	7,563	16,600*	—	13,453	18,307	14,089*	10,969	9,884	10,313	18,835*
Revenue from contracts with customers	20,624	21,431	7,563	16,600*	—	13,453	18,307	14,089*	10,969	9,884	10,313	18,835*
Cost of revenue	10,643	10,473	4,407	8,152*	—	8,053	11,124	9,817*	7,250	7,339	6,945	10,816*
Gross profit	9,981	10,958	3,156	8,448*	—	5,400	7,183	4,272*	3,719	2,545	3,368	8,019*
Research and development	2,457	1,972	2,139	2,151*	—	2,276	3,140	2,686*	2,849	2,972	3,167	3,645*
Selling, general and administrative	3,409	3,518	3,063	3,756*	—	4,637	5,162	3,926*	4,717	4,434	4,430	5,580*
Total operating expenses	5,866	5,490	5,202	5,907*	—	6,913	8,302	7,476*	7,785	7,193	7,597	9,225*
Operating income (loss)	4,115	5,468	(2,046)	2,541*	—	(1,513)	(1,119)	(3,204)*	(4,066)	(4,648)	(4,229)	(1,206)*
Other income (expense)	(6)	10	(2)	(10)*	—	40	(25)	(4)*	1,051	10	(12)	3*
Income tax expense (benefit)	16	20	7	(20,741)*	—	(217)	(231)	(87)*	(752)	(1,214)	(798)	(1,846)*
Net income (loss)	4,674	6,089	(1,471)	23,864*	660	(1,028)	(643)	(2,899)*	(2,084)	(3,230)	(3,203)	1,391*
Earnings per share, basic USD per share	0.16	0.21	(0.05)	—	0.02	(0.03)	(0.02)	—	(0.07)	(0.11)	(0.10)	0.04*
Earnings per share, diluted USD per share	0.16	0.20	(0.05)	—	0.02	(0.03)	(0.02)	—	(0.07)	(0.11)	(0.10)	0.04*
Weighted average shares, basic thousands of shares	28,649	29	28,866	—	29,107	29,659	29,733	—	29,923	30,177	30,695	31,881*
Weighted average shares, diluted thousands of shares	29,632	30	28,866	—	29,632	29,659	29,733	—	29,923	30,177	30,695	31,881*

Balance sheet

CSV

Fiscal quarters (AEHR's year ends in late May)

In thousands of dollars	Q1 FY24Aug 31, 2023	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25Nov 29, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 30, 2025	Q1 FY26Aug 29, 2025	Q2 FY26Nov 28, 2025	Q3 FY26Feb 27, 2026	Q4 FY26May 29, 2026
Cash and cash equivalents	50,955	50,514	47,581	49,159	—	32,217	29,411	24,529	22,708	30,835	36,911	116,358
Short-term investments	0	0	0	0	—	—	—	—	—	—	—	—
Inventory	31,557	33,817	38,085	37,470	—	43,776	42,329	41,997	41,842	42,723	41,162	41,354
Prepaid and other current assets	540	2,861	1,215	1,423	—	5,195	7,968	8,061	6,447	4,349	6,019	9,263
Total current assets	96,213	91,765	92,349	97,848	—	88,521	91,699	88,778	84,052	88,189	95,900	184,448
Property and equipment, net	3,083	3,185	3,150	3,253	3,503	4,306	7,028	8,969	9,001	8,987	9,277	8,940
Right-of-use asset	5,951	5,987	5,863	5,734	—	6,038	5,749	9,601	9,422	9,272	9,089	8,901
Goodwill	—	—	—	0	—	10,742	10,742	10,719	10,719	10,719	10,719	10,719
Total assets	105,469	101,175	101,596	127,912	—	142,280	145,607	148,508	144,092	148,734	157,046	246,694
Accounts payable	8,328	4,183	4,979	5,332	—	4,854	6,961	6,728	3,380	3,548	2,103	6,754
Accrued liabilities	4,536	3,232	3,287	3,366	—	5,392	—	—	—	—	—	—
Total current liabilities	19,253	7,959	9,180	10,508	—	11,717	16,064	15,638	11,913	8,305	8,742	17,855
Lease liability, non-current	5,997	6,016	5,878	5,732	—	5,574	5,267	9,921	9,710	9,578	9,419	9,256
Total liabilities	25,324	14,021	15,099	16,319	—	19,099	21,397	25,637	21,698	17,958	18,254	27,183
Accumulated deficit	(47,632)	(41,543)	(43,014)	(19,150)	—	(19,518)	(20,161)	(23,060)	(25,144)	(28,374)	(31,577)	(30,186)
Total stockholders' equity	80,145	87,154	86,497	111,593	—	123,181	124,210	122,871	122,394	130,776	138,792	219,511
Total liabilities and equity	105,469	101,175	101,596	127,912	—	142,280	145,607	148,508	144,092	148,734	157,046	246,694
Common shares outstanding (cover page) thousands of shares	28,799	28,849	28,915	29,007	29,631	29,712	29,771	29,915	30,007	30,627	31,453	32,620

Cash flows

CSV

Fiscal quarters (AEHR's year ends in late May)

In thousands of dollars	Q1 FY24Aug 31, 2023	Q2 FY24Nov 30, 2023	Q3 FY24Feb 29, 2024	Q4 FY24May 31, 2024	Q1 FY25Aug 31, 2024	Q2 FY25Nov 29, 2024	Q3 FY25Feb 28, 2025	Q4 FY25May 30, 2025	Q1 FY26Aug 29, 2025	Q2 FY26Nov 28, 2025	Q3 FY26Feb 27, 2026	Q4 FY26May 29, 2026
Net income (loss)	4,674	6,089	(1,471)	23,864*	660	(1,028)	(643)	(2,899)*	(2,084)	(3,230)	(3,203)	1,391*
Stock-based compensation	522	638*	584*	774*	—	1,075*	1,796*	1,421*	1,671	1,841*	1,384*	1,865*
Net cash from operating activities	3,901	(545)*	(2,824)*	1,224*	—	(5,873)*	(1,605)*	(2,302)*	(282)	(1,171)*	(3,689)*	1,832*
Purchases of property and equipment	284	156*	263*	46*	—	321*	1,656*	2,818*	1,391	467*	74*	134*
Net cash from investing activities	17,716	(156)*	(263)*	(46)*	—	(321)*	(2,116)*	(2,818)*	(1,391)	(2,268)*	(74)*	(134)*
Proceeds from issuing common stock	318	774*	178*	537*	—	775*	63*	515*	170	897*	58*	1,075*
Net cash from financing activities	(694)	254*	158*	421*	—	594*	(114)*	251*	(158)	9,777*	9,828*	77,764*
Net change in cash	20,901	(441)*	(2,933)*	1,578*	—	(5,612)*	(3,807)*	(4,881)*	(1,822)	6,327*	6,076*	79,447*

Compare with peers

SIC 3825 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3825 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Aehr Test Systems	116,358	18,835*	1,832*	32.6M	—	Q4 FY26 10-KMay 29, 2026
Transcat	5,758	97,090	10,148*	9.4M	—	Q2 FY27 10-QSep 26, 2026
EyePoint	110,458	507	(62,348)*	86.2M	2.9 quarters	Q2 FY26 10-QJun 30, 2026
Allient	42,088	153,770	13,954*	17.0M	—	Q2 FY26 10-QJun 30, 2026
Cohu	272,303	172,956	5,600*	47.3M	—	Q3 FY26 10-QSep 26, 2026
Cytek Biosciences	73,846	48,140	1,367*	130.0M	—	Q2 FY26 10-QJun 30, 2026
Senseonics Holdings	44,753	14,483	(30,138)*	52.9M	4.7 quarters	Q2 FY26 10-QJun 30, 2026
Pacific Biosciences of California	61,003	39,007	(35,583)*	310.8M	6.7 quarters	Q2 FY26 10-QJun 30, 2026
Mesa Laboratories	30,695	60,138	14,736	5.6M	—	Q1 FY27 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.